Oxidative stress and lipid peroxidation are upstream of amyloid pathology

Neurobiology of Disease

Volumn 84, Issue , 2015, Pages 109-119

  Arimon, Muriel ^a,b   Takeda, Shuko ^a,c   Post, Kathryn L ^a   Svirsky, Sarah ^a   Hyman, Bradley T ^a   Berezovska, Oksana ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUT DE NEUROCIÈNCIES   (Spain)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

4 Hydroxynonenal; Alzheimer's disease; Amyloid beta; Lipid peroxidation; Microdialysis; Oxidative stress; Presenilin; Secretase

Indexed keywords

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; GAMMA SECRETASE; PRESENILIN 1; THYMIDINE DIPHOSPHATE; 4,4'-DIPYRIDYL DISULFIDE; 4-HYDROXY-2-NONENAL; ACETYLCYSTEINE; ALDEHYDE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIOXIDANT; DISULFIDE; MEMBRANE PROTEIN; N-ACETYLCYSTEINAMIDE; NICASTRIN PROTEIN; PEPTIDE FRAGMENT; PRESENILIN 1, MOUSE; PYRIDINE DERIVATIVE; SECRETASE;

ANIMAL TISSUE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVITY; HIPPOCAMPUS; INTERSTITIAL FLUID; LIPID PEROXIDATION; MICRODIALYSIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROCESSING; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ACETYLCYSTEINE; ALDEHYDES; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIOXIDANTS; BRAIN; DISULFIDES; LIPID PEROXIDATION; MEMBRANE GLYCOPROTEINS; MICE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PRESENILIN-1; PYRIDINES;

EID: 84933573947     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.013     Document Type: Article

References (59)

1. Atamna H., Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(9):3381-3386.
2. Berezovska O., Frosch M., et al. The Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons. Brain Res. Mol. Brain Res. 1999, 69(2):273-280.
3. Berezovska O., Lleo A., et al. Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J. Neurosci. 2005, 25(11):3009-3017.
4. Bergmans B.A., De Strooper B. gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010, 9(2):215-226.
5. Borchelt D.R., Thinakaran G., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17(5):1005-1013.
6. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 2002, 36(12):1307-1313.
7. Butterfield D.A., Hensley K., et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J. Neurochem. 1997, 68(6):2451-2457.
8. Butterfield D.A., Griffin S., et al. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J. Alzheimers Dis. 2002, 4(3):193-201.
9. Butterfield D.A., Reed T., et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 2006, 397(3):170-173.
10. Cai Z., Zhao B., et al. Oxidative stress and beta-amyloid protein in Alzheimer's disease. Neruomol. Med. 2011, 13(4):223-250.
11. Chavez-Gutierrez L., Bammens L., et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012, 31(10):2261-2274.
12. Cirrito J.R., May P.C., et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 2003, 23(26):8844-8853.
13. Cutler R.G., Kelly J., et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(7):2070-2075.
14. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007, 8(2):141-146.
15. Esterbauer H., Schaur R.J., et al. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11(1):81-128.
16. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408(6809):239-247.
17. Garcia-Alloza M., Dodwell S.A., et al. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J. Neuropathol. Exp. Neurol. 2006, 65(11):1082-1089.
18. Guix F.X., Wahle T., et al. Modification of gamma-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease. EMBO Mol. Med. 2012, 4(7):660-673.
19. Gwon A.R., Park J.S., et al. Oxidative lipid modification of nicastrin enhances amyloidogenic gamma-secretase activity in Alzheimer's disease. Aging Cell 2012, 11(4):559-568.
20. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
21. Harris M.E., Hensley K., et al. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 1995, 131(2):193-202.
22. Isoo N., Sato C., et al. Abeta42 overproduction associated with structural changes in the catalytic pore of gamma-secretase: common effects of Pen-2 N-terminal elongation and fenofibrate. J. Biol. Chem. 2007, 282(17):12388-12396.
23. Kelleher R.J., Shen J. Genetics. Gamma-secretase and human disease. Science 2010, 330(6007):1055-1056.
24. Krstic D., Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 2013, 9(1):25-34.
25. Kuperstein I., Broersen K., et al. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010, 29(19):3408-3420.
26. Lewczuk P., Esselmann H., et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25(3):273-281.
27. Lleo A., Berezovska O., et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med. 2004, 10(10):1065-1066.
28. Lovell M.A., Markesbery W.R. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 2001, 58(3):392-396.
29. Mangialasche F., Polidori M.C., et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res. Rev. 2009, 8(4):285-305.
30. Mark R.J., Lovell M.A., et al. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 1997, 68(1):255-264.
31. Mark R.J., Pang Z., et al. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 1997, 17(3):1046-1054.
32. McLellan M.E., Kajdasz S.T., et al. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 2003, 23(6):2212-2217.
33. Nemoto S., Takeda K., et al. Role for mitochondrial oxidants as regulators of cellular metabolism. Mol. Cell. Biol. 2000, 20(19):7311-7318.
34. Nishikawa T., Edelstein D., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404(6779):787-790.
35. Pratico D., Uryu K., et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001, 21(12):4183-4187.
36. Reed T.T., Pierce W.M., et al. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J. Cell. Mol. Med. 2009, 13(8B):2019-2029.
37. Reed T.T., Pierce W.M., et al. Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res. 2009, 1274:66-76.
38. Sajdel-Sulkowska E.M., Marotta C.A. Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. Science 1984, 225(4665):947-949.
39. Sayre L.M., Zelasko D.A., et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 1997, 68(5):2092-2097.
40. Serneels L., Van Biervliet J., et al. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 2009, 324(5927):639-642.
41. Shen J., Kelleher R.J. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(2):403-409.
42. Shichiri M., Yoshida Y., et al. alpha-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic. Biol. Med. 2011, 50(12):1801-1811.
43. Subramaniam R., Roediger F., et al. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 1997, 69(3):1161-1169.
44. Subramanian R., Tam J., et al. Novel cytochrome p450 bioactivation of a terminal phenyl acetylene group: formation of a one-carbon loss benzaldehyde and other oxidative products in the presence of N-acetyl cysteine or glutathione. Chem. Res. Toxicol. 2011, 24(5):677-686.
45. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis. 2010, 19(1):341-353.
46. Sun S.Y. N-acetylcysteine, reactive oxygen species and beyond. Cancer Biol. Ther. 2010, 9(2):109-110.
47. Takeda S., Sato N., et al. Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouse. Neuroscience 2011, 186:110-119.
48. Tamagno E., Bardini P., et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 2002, 10(3):279-288.
49. Tamagno E., Parola M., et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 2005, 92(3):628-636.
50. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 2003, 42(4):318-343.
51. Uemura K., Lill C.M., et al. Allosteric modulation of PS1/gamma-secretase conformation correlates with amyloid beta(42/40) ratio. PLoS One 2009, 4(11):e7893.
52. Uemura K., Farner K.C., et al. Substrate docking to gamma-secretase allows access of gamma-secretase modulators to an allosteric site. Nat. Commun. 2010, 1:130.
53. Wahlster L., Arimon M., et al. Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. Acta Neuropathol. 2013, 125(2):187-199.
54. Wang R., Tang P., et al. Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(2):353-358.
55. Williams T.I., Lynn B.C., et al. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging 2006, 27(8):1094-1099.
56. Wiltfang J., Esselmann H., et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J. Neurochem. 2007, 101(4):1053-1059.
57. Wolfe M.S. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007, 8(2):136-140.
58. Xia D., Watanabe H., et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron 2015, 85(5):967-981.
59. Xie H., Hou S., et al. Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(19):7904-7909.